Advanced Cancer: Analyzing Patient Discussions

Advanced Cancer: Analyzing Patient Discussions

0.5 hours | ACCME, ANCC
COURSE DESCRIPTION

Research suggests that physicians who manage patients with advanced cancer often struggle with whether and how best to convey sensitive information about prognoses to these individuals for many reasons. Some studies indicate that physicians do not share information with patients about a terminal cancer prognosis despite the fact that end-of-life care discussions are often wanted by patients. Improving doctor-patient communication at the end of life may enhance the delivery of patient-centered care. Physicians often believe that patients who have an accurate prognostic understanding tend to experience higher levels of anxiety and a worse quality of life. To the contrary, research has shown that patients who are engaged in end-of-life discussions do not appear to be more depressed or worrisome.

Activities Included:

CME Information

Content

Quiz

Evaluation

Standard: Free

Incorporating TKI Therapy into CML Management

ACCME | ANCC | ACPE


OVERVIEW
The advent of tyrosine kinase inhibitor (TKI) therapy that targets the oncogenic BCR-ABL protein has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires long-term pharmacological disease management. Monitoring patient response to TKI therapy at recommended time intervals is the cornerstone of patient management and is an important milestone for predicting long-term treatment outcome. The National Comprehensive Cancer Network (NCCN) therapy recommendations for first-line TKIs include first-generation imatinib or second-generation nilotinib or dasatinib. These interactive case studies will review the NCCN guidelines for TKI therapy for treating high- and low-risk patients and will also address the considerations necessary for choosing the best treatment plan, including risk stratification of patients, pregnancy, patients who do not meet their milestones, and if, when, and how to switch therapy.

Activities Included:

CME/CE Information


Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia

ACCME | ANCC | ACPE


OVERVIEW
The advent of tyrosine kinase inhibitor therapy has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires long-term pharmacological disease management. But, each treatment comes with its own risks and benefits, which can substantially affect patients’ quality of life beyond simply extending life. In addition, treatment options change throughout the course of CML. Shared decision-making (SDM) is a process that aims to give patients the care that they want by making informed decisions about treatment options, while clinicians also consider patient preferences and values. SDM is a 2-way discussion designed for the patient and clinician to arrive together at the best treatment plan for that patient. This web-based video activity will employ a case study scenario to show how SDM can be implemented during the course of treating patients with CML. The video activity will also offer guidance on how to implement SDM into each clinical encounter while being mindful of today’s time constraints and complex medical technologies. The video features 2 experienced hematology/oncology clinicians (a physician and a nurse) as well as the executive director of a patient advocacy organization.

Activities Included:

CME/CE Information

Pre-Test

Video

Post-Test

Evaluation